NVCTHealthcare · BiotechnologyThe 6 Wall Street analysts covering Nuvectis Pharma, Inc. hold a median 12-month price target of $35 — +94.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Nuvectis Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (24): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NVCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +94.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $39 |
| 24 Aug 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 24 Aug 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 6 July 2026 | Roth Capital | Maintains | Buy | $20 → $33 |
| 6 July 2026 | Roth Capital | Maintains | Buy | — |
| 22 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2025 | Maxim Group | Initiates | Buy | — |
| 17 Mar 2025 | Laidlaw & Co. | Initiates | Buy | — |
| 25 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 July 2022 | Ladenburg Thalmann | Initiates | Buy | — |
| 10 May 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Mar 2022 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVCT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Nuvectis Pharma, Inc. returned +198.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 2% of US stocks
Cheaper than 90% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 7% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nuvectis Pharma, Inc. has a market value of $592.5M and an enterprise value of $569.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$27.8M.
Free cash flow in the twelve months to 30 June 2026: −$19.5M.
Trailing P/E: −13.7×; forward P/E: −18.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nuvectis Pharma, Inc. employs 16 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nuvectis Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nuvectis Pharma announced that members of its senior management will participate in the Maxim Growth Summit 2026 on October 14, 2026, in New York.
Why it matters — The announcement provides NVCT watchers with information about the company’s upcoming management participation at an investor summit.
Nuvectis Pharma announced that NXP200 (HSK42360), an oral, brain-penetrant, paradox-breaker BRAF inhibitor, was granted Breakthrough Therapy Designation by China's Center for Drug Evaluation for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma.
Why it matters — A NVCT watcher would care because this is a regulatory milestone that may expedite the development and review of NXP200 in a serious oncology indication in China.
Nuvectis Pharma announced that senior management will participate in the 2026 Cantor Global Healthcare Conference, including a fireside chat scheduled for Friday, September 11, 2026 at 9:10 AM ET. The announcement was made by the company on September 3, 2026.
Why it matters — A NVCT watcher would care because senior management's participation in investor conferences gives investors an opportunity to hear directly from company leadership about its clinical-stage programs.
Nuvectis Pharma's stock rose roughly 97% over three months, a gain attributed to optimism surrounding its expanding pipeline, including the NXP100 and NXP200 programs as new value drivers.
Why it matters — NVCT watchers would care because the surge reflects growing market confidence in the company's pipeline expansion beyond its existing programs.
Nuvectis Pharma, a clinical-stage biopharmaceutical company developing therapies for complement-related conditions and oncology, reported its financial results for the second quarter of 2026 and provided an update on recent business progress. The announcement was made via press release on August 4, 2026.
Why it matters — A quarterly financial and business update provides NVCT watchers with the company's latest operational and financial status.
The 6 Wall Street analysts covering Nuvectis Pharma, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Nuvectis Pharma, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuvectis Pharma, Inc. 65 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Nuvectis Pharma, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +94.4% from the last close, and Ticker Nerd's factor model ranks Nuvectis Pharma, Inc. 65 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nuvectis Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.
Nuvectis Pharma, Inc. returned +198.5% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need.
The most recent item we track (GlobeNewsWire, 9 Oct 2026): "Nuvectis Pharma to Participate in the Maxim Growth Summit 2026". Nuvectis Pharma announced that members of its senior management will participate in the Maxim Growth Summit 2026 on October 14, 2026, in New York.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need. The company works on targeted small-molecule therapies designed for genetically defined cancer patient populations, with its current pipeline centered on NXP800 and NXP900. NXP800 is being developed for specific ovarian cancer settings, while NXP900 is designed to inhibit SRC family kinases, including SRC and YES1, in solid tumors. Based in Fort Lee, New Jersey, Nuvectis Pharma operates as a single-segment biotechnology business centered on oncology drug development and clinical research.
CEO Mr. Ron Bentsur M.B.A. · 16 employees · United States · https://www.nuvectis.com
